Clinical Trials Logo

Opioid-induced Constipation clinical trials

View clinical trials related to Opioid-induced Constipation.

Filter by:

NCT ID: NCT03060512 Completed - Clinical trials for Opioid Induced Constipation

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Start date: March 2, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.

NCT ID: NCT02813369 Terminated - Clinical trials for Opioid Induced Constipation

Naloxegol Health Outcome Post Authorisation Safety Study

Start date: September 2016
Phase:
Study type: Observational

This post-authorization observational safety study (PASS) monitors clinically important identified and potential risks within a cohort of patients treated with naloxegol, including the occurrence of bowel perforation, acute myocardial infarction (MI), stroke, cardiovascular (CV)-specific mortality, all-cause mortality, hypertension, opioid withdrawal, abdominal pain, diarrhea, syncope, and change in pain severity. This study is part of a broader post-marketing commitment to augment routine evaluation of the safety profile of naloxegol in clinical practice.

NCT ID: NCT02813356 Active, not recruiting - Clinical trials for Opioid Induced Constipation

Naloxegol US PMR CV Safety.

Start date: June 24, 2016
Phase:
Study type: Observational

The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically

NCT ID: NCT02813148 Completed - Clinical trials for Opioid Induced Constipation

Naloxegol Drug Utilization Post Authorisation Safety Study

Start date: August 2015
Phase:
Study type: Observational

This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway, Sweden, and Germany.

NCT ID: NCT02574819 Recruiting - Clinical trials for Opioid-induced Constipation

Study of Methylnaltrexone in Opioid-Induced Constipation Patients

Start date: April 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind , placebo-controlled trail to investigate the safety and efficacy of subcutaneous methylnaltrexone for treating opioid-induced constipation in patients with advanced illness.

NCT ID: NCT02571881 Active, not recruiting - Pain, Postoperative Clinical Trials

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section

oksisektio
Start date: October 2012
Phase: Phase 4
Study type: Interventional

Constipation is common in pregnant women. Surgery, anaesthesia and opioid analgesics may further impair bowel function. The aim of the present study was to evaluate if oxycodone-naloxone combination compared to oxycodone reduced bowel dysfunction in patients undergoing caesarean section.

NCT ID: NCT02270983 Completed - Clinical trials for Opioid-Induced Constipation

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

Start date: October 31, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the safety and efficacy of linaclotide for the treatment of opioid-induced constipation (OIC), in adults receiving stable opioid treatment for chronic non-cancer pain that has been present for a minimum of 3 months. This study included up to a 4-week Screening Period, and a 2 to 3-week Pretreatment Period. Patients meeting the entry criteria were randomized to 1 of 2 doses of linaclotide or placebo once per day for 8 weeks. This 8-week study assessed the effects of linaclotide on bowel movement frequency, as well as other bowel symptoms of OIC.

NCT ID: NCT01993940 Completed - Clinical trials for Opioid-induced Constipation

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

Start date: November 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in subjects with non-malignant chronic pain who are not using laxatives

NCT ID: NCT01965652 Completed - Clinical trials for Opioid-induced Constipation

Long Term Safety of Naldemedine

Start date: September 24, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.

NCT ID: NCT01965158 Completed - Clinical trials for Opioid-induced Constipation

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

Start date: August 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in subjects with non-malignant chronic pain who are not using laxatives